used in this study: anti-ICAM-1 (mouse immunoglobulin (mIg) G2b, LB-2; Becton Dickinson, San Jose, CA, USA), anti-ICAM-2 (mIgG1, B-T1; Immunotech, Marseille, France), anti-ICAM-3 (mIgG2a, HP2/19; Immunotech, Marseille, France), antivascular cell adhesion molecule-1 (VCAM-1) (mIgG1, 51-10c9; Pharmingen, San Diego, CA, USA), anti-E-selectin (mIgG, 68-5H11; Pharmingen, San Diego, CA, USA). Staurosporin and genistein were obtained from Wako Pure Chemicals Ltd (Tokyo, Japan). NF-kB SN-50, an inhibitor of nuclear factor kappa B (NF-κB) nuclear translocation, was purchased from Biomol (Plymouth Meeting, PA, USA). Monoclonal mouse anti-human interferon gamma (IFN-γ) antibody were obtained from Genzyme (Cambridge, MA, USA).
Cell lines and cell culture
NA and HSC-4, cancer cell lines established from patients with SCC of the tongue, were maintained as monolayers in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 units ml -1 penicillin and 100 µg ml -1 streptomycin (complete medium) (Hori et al, 1994) . Subconfluent monolayers of NA cells or HSC-4 cells were employed in all experiments.
Cytotoxic effects of anticancer agents on NA cells
NA cells were seeded in a flat-bottomed 96-well microplate by adding 0.2 ml of complete medium containing 3 × 10 4 cells. After 24 h incubation, NA cells were treated with various concentrations of CDDP and/or 5-FU. After a further 18 h incubation, the medium was removed, and cells were washed twice with phosphate-buffered saline (PBS), and fixed and stained for 30 min with 2% ethanol containing 0.2% crystal violet. Bound dye was eluted with 0.1 ml of 1% sodium dodecyl sulphate. Absorbance was measured at 570 nm on a microplate reader MR 5000 (Dynatech) (Kamijo et al, 1989) . The percentage of cytotoxicity was calculated from the mean OD by the following equation: % cytotoxicity = 
Flow cytometry
Antigens were detected on cell surfaces by indirect immunofluorescence followed by standard flow cytometric analysis. NA cells or HSC-4 cells (2 × 10 6 cells) were incubated in the presence or absence of CDDP and/or 5-FU for 18 h. Cells were washed with PBS at 4°C and incubated with 500 ng to 1 µg of primary antibodies for 30 min at 4°C. Cells were washed three times with PBS followed by a 30 min incubation with the secondary antibody, fluoroscein isothiocyanate (FITC)-conjugated goat antimouse IgG (Becton Dickinson, San Jose, CA, USA). Cells were washed three times with PBS and resuspended with 100-200 µl of 1% paraformaldehyde PBS. Samples were then analysed using a FACscan flow cytometer (Becton Dickinson, San Jose, CA, USA). In some experiments, cells were pretreated with genistein (100 ng ml -1 ), staurosporin (10 -9 M) or NF-κB SN-50 (18 µM) for 30 min before addition of anticancer agents.
Reverse transcriptase-polymerase chain reaction
NA cells (1 × 10 6 cells) were incubated with CDDP and/or 5-FU for 4 h. For reverse transcriptase-polymerase chain reaction (RT-PCR) analysis, cytoplasmic RNA was extracted by the guanidine isothiocyanate-phenol-chloroform extraction method. To ensure that the amplification products were from the mRNA being probed, RNA samples were treated with DNase I (Gibco BRL, Gaithersburg, MD, USA) at room temperature for 15 min. First-strand cDNA synthesis was carried out as described previously (Sumitani et al, 1998) . Briefly, 1 µg of total RNA was reverse transcribed to single-stranded cDNA in 25-µl of reaction mixture containing 1 × RT buffer (50 mM Tris-HCl pH 8.3, 10 mM potassium chloride, 10 mM magnesium chloride and 10 mM dithiothreitol (DTT)), 0.5 µg of Rnasin (Promega, Madison, WI, USA), 0.5 mM of each dNTP (Pharmacia Biotech, Tokyo, Japan), 2.0 µg of random primer and 5 units of avian myeloblastosis virus (AMV) reverse transcriptase (Gibco BRL, Gaithersburg, MD, USA). The reverse transcriptation reaction mixture was incubated for 90 min at 37°C, heated at 98°C to inactivate the enzyme, and quickly chilled to 10°C. A 5 µl aliquot of cDNA was mixed with 45 µl of PCR mixture containing 1 × PCR buffer, 500 mM of each dNTP, 0.4 mM of each primer and 1 unit of Taq DNA polymerase (Promega, Madison, WI, USA). PCR was performed using a programmed temperature control system (Astec, Fukuoka, Japan) set for 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min. A 10 µl aliquot of each reaction mixture was electrophoresed on a 1% agarose gel, and PCR products were visualized by ethidium bromide staining. To normalize for the amount of input RNA, RT-PCR was performed with primers for the constitutively expressed glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene.
The primers used for RT-PCR are as follows: ICAM-1: sense, 5′ TATGGCAACGACTCCTTCT 3′; antisense, 5′ CATTCAGCG-TCACCTTGG 3′; amplified product: 238 bp. GAPDH: sense, 5′ TGAAGGTCGGAGTCAACGGATTTGGT 3′; antisense, 5′ CATGTGGGCCATGAGGTCCACCAC 3′; amplified product: 983 bp. IL-1α: sense, 5′ CAAGGAGAGCATGGTGGTAGTAG-CAACCAACG 3′; antisense, 5′ TAGTGCCGTGAGTTTCCCA-GAAGAAGGAGG 3′; amplified product: 491 bp. IL-1β: sense, 5′ ATGGCAGAAGTACCTAAGCTCGC 3′; antisense, 5′ AC-ACAAATTGCATGGTGAAGTCAGTT 3′; amplified product: 801 bp. IFN-γ: sense, 5′ GCATCGTTTTGGGTTCTCTTGGCTG-TTACTGC 3′; antisense, 5′ CTCCTTTTTCGCTTCCCTGTTTT-AGCTGCTGG 3′; amplified product: 427 bp. TNF-α: sense, 5′ GAGTGACAAGCCTGTAGCCCATGTTGTAGCA 3′; antisense, 5′ GCAATGATCCCAAAGTAGACCTGCCCAGACT 3′; amplified product: 444 bp.
Enzyme-linked immunosorbent assay
NA cells (4 × 10 4 cells in 200 µl of complete medium) were incubated in the presence or absense of CDDP and/or 5-FU for 18 h. Aliquots of culture medium were harvested and cytokine levels in the culture medium were determined using specific enzyme-linked immunosorbent assay (ELISA), (Endogen, Boston, MA, USA), according to the manufacturer's instructions.
Electrophoretic mobility shift analysis
Electrophoretic mobility shift analysis (EMSA) was performed as previously described (Song et al, 1997) . Nuclear extracts were prepared by treating the cell pellet with cold buffer (10 mmol l -1 EGTA, 1 mmol l -1 DTT, and 0.5 mmol l -1 phenylmethylsulphonyl fluoride (PMSF) for 15 min to allow cells to swell, and then 25 µl 10% NP-40 was added and the nuclei were pelleted. The nuclear pellet was resuspended in buffer (20 mmol l -1 Hepes, pH 7.9, 0.4 mol l -1 sodium chloride, 1 mmol l -1 EDTA, 1 mmol l -1 EGTA, 1 mmol l -1 DTT and 1 mmol l -1 PMSF) for 15 min at 4°C. Debris was pelleted, and supernatants were frozen at -70°C. Nuclear extracts (5-7 µg protein) prepared from NA cells were incubated with 50 000 cpm (0.5 ng) 32 P-end-labelled double-stranded synthetic deoxyoligonucleotide probes for 30 min at room temperature in a 20 ml reaction volume containing 12% glycerol, 12 mmol l -1 Hepes-NaOH (pH 7.9), 60 mmol l -1 potassium chloride, 5 mmol l -1 magnesium chloride, 4 mmol l -1 Tris hydrochloride (pH 7.9), 0.6 mmol l -1 EDTA (pH 7.9), 0.6 mmol l -1 DTT and 1 µg poly (dI)(dC). Protein-DNA complexes were resolved in 5% native polyacrylamide gels pre-electrophoresed for 30 min at room temperature in 0.25 × TBE buffer (22.5 mM Tris-borate and 0.5 mM EDTA, pH 8.3). Gels were dried and exposed overnight to X-ray film (Eastman Kodak, Rochester, NY, USA) with an intensifying screen at -70°C. The oligonucleotide probe used in this study to detect NF-κB was 5′-GCTCCGGAATTTCCAAGC-3′.
RESULTS

Cytotoxic effects of CDDP and/or 5-FU on NA cells
Both CDDP and 5-FU dose-dependently exerted cytotoxic activity against NA cells (Figure 1 ). The concentration of CDDP or 5-FU needed for 50% reduction of the OD 570 in the control was approximately 500 µg ml -1 . CDDP and/or 5-FU exert both cytotoxic effect and antiproliferative effect against NA cells. Trypan blue dye exclusion assay revealed that both agents were dominantly cytotoxic at concentrations exceeding 100 µg ml -1 , though they were antiproliferative and less cytotoxic for NA cells at lower concentrations (data not shown). For subsequent experiments, we employed suboptimal doses of CDDP (100 µg ml -1 ) or 5-FU (100 µg ml -1 ). When both agents (100 µg ml -1 ) were added simultaneously, no synergistic effect was observed ( Figure 1 ). The viabilities of NA cells treated with CDDP (100 µg ml -1 ) and 5-FU (100 µg ml -1 ), alone or in combination, were approximately 99% as determined by trypan blue dye exclusion assays.
Effects of CDDP and/or 5-FU on the expression of ICAM-1, ICAM-2 and ICAM-3 on NA cells
To determine the effect of CDDP and/or 5-FU on the expression of ICAM-1, ICAM-2 and ICAM-3 on cell surface, we employed flow-cytometric analysis. Cell surface antigen expression on NA cells was evaluated 18 h after incubation with CDDP and/or 5-FU, and the results were compared to untreated control cells. As shown in Figure 2A 
RT-PCR analysis
It was reported that ICAM-1 mRNA can be detected within a few hours after stimulation with IFN-γ in monocytes (Song et al, 1997) . Therefore, the expression of ICAM-1 mRNA was examined in NA cells at 4 h after incubation with CDDP and/or 5-FU. To evaluate the effect of CDDP and/or 5-FU on the expression of ICAM-1 mRNA in NA cells, we employed RT-PCR method. RT-PCR analysis revealed that the expression of ICAM-1 mRNA was synergistically induced by CDDP and 5-FU in NA cells, whereas CDDP or 5-FU alone did not induce ICAM-1 mRNA expression ( Figure 3A ). Densitometrical analysis confirmed the synergistic induction of ICAM-1 mRNA in NA cells treated with CDDP and 5-FU ( Figure 3B ).
Effects of protein kinase inhibitors on the expression of ICAM-1 induced by CDDP and/or 5-FU
To determine whether ICAM-1 induction by CDDP and 5-FU is related to protein phosphorylation, NA cells were pretreated with genistein (100 ng ml -1 ) or staurosporin (10 -9 M) for 30 min. After pretreatment, cells were incubated with CDDP and 5-FU for 18 h, and the expression of ICAM-1 on NA cells were analysed by flow cytometry. Induction of ICAM-1 on NA cells by CDDP and 5-FU was inhibited by the pretreatment with genistein, though pretreatment with staurosporin did not alter ICAM-1 expression on NA cells (Figure 4 ).
Effects of CDDP and 5-FU on DNA binding activity on ICAM-1 NF-κB
The ICAM-1 promoter contains NF-κB sites located distal (nucleotides -540 to -528) and proximal (nucleotides -228 to -217) (Song et al, 1997) . We employed EMSA to examine whether CDDP and 5-FU induces NF-κB binding activity in NA cells, since recent data indicate that IFN-γ, a potent inducer of ICAM-1 on epithelial cells, increases DNA binding activity of the proximal NF-κB site (Song et al, 1997) . Treatment with CDDP and 5-FU increased DNA binding activity of the proximal NF-κB 
Effects of CDDP and/or 5-FU on the expression of E-selectin and VCAM-1 on NA cells
The expression of E-selectin and VCAM-1 were evaluated 18 h after incubation with CDDP and/or 5-FU, and compared to levels in untreated cells. As shown in Figure 7A , E-selectin was constitutively ) for 30 min (lane 2, 4), and nuclear extracts were prepared. Radiolabelled oligonucleotide comprising the proximal ICAM-1 NF-κB site was incubated with 5 mg of nuclear extracts as described in Materials and Methods, and the amounts of specific NF-κB binding complexes were compared to control nuclear extracts 
Effects of CDDP and/or 5-FU on the expression of ICAM-1, ICAM-2 and ICAM-3 on HSC-4 cells
To confirm that the synergistic effects of CDDP and 5-FU reported in this study are not specific to NA cells, the effects of CDDP and/or 5-FU on the expression of ICAM-1, ICAM-2 and ICAM-3 on HSC-4 cells were examined. Since HSC-4 cells were more sensitive for cytotoxicity induced by CDDP and/or 5-FU than NA cells, HSC-4 cells were incubated in the presence of CDDP (10 µg ml -1 ) and 5-FU (100 µg ml -1 ) for 18 h, and cell surface antigen expression on HSC-4 cells was evaluated. As shown in Figure 8A , ICAM-1 was constitutively expressed on untreated HSC-4 cells (MFI was 6.80). Although CDDP or 5-FU alone did not induce the expression of ICAM-1 on HSC-4 cells (MFI was 9.21 and 10.63 respectively), expression of ICAM-1 was synergistically induced by treatment with CDDP and 5-FU (MFI was 20.34). Figures 8B and C 
DISCUSSION
Although the principal mechanism of anticancer drugs to eliminate cancer cells is induction of apoptosis (Huschtscha et al, 1996; Ueda et al, 1997) , mechanisms to eliminate cancer cells which has escaped from apoptosis, including activation of the host immune system, might also play a role. Previous studies have shown mechanisms by which CDDP and 5-FU synergistically exert antitumour activity (Scanlon et al, 1986; Esaki et al, 1992 ), but it is not known whether these agents can stimulate the host immune system.
Macrophages and T lymphocytes play essential roles in defence against cancer cells. Exclusion of cancer cells in vivo involves several cytotoxic effector mechanisms. For example, secretion of nitric oxide (NO), an unstable free radical gas, is nominated as a major effector molecule for macrophage cytotoxicity. We have recently reported that NO is essential for host immune responses against infectious agents and cancer cells (Kamijo et al 1993a (Kamijo et al , 1993b Sumitani et al, 1997) . Cytolytic T-cells must recognize antigens presented by MHC class I molecules or certain cell adhesion molecules to be effective (Vanky et al, 1990) . ICAM-1, an immunoglobulin supergene family member, is found on lymphocytes and monocytes and can be induced on endothelial cells by cytokines, such as IL-1, TNF and IFN (Pohlman et al, 1986; Staunton et al, 1988; Buckle and Hogg, 1990; Springer et al, 1990; Most et al, 1992) . Several studies (Vanky et al, 1990; Bouillon et al, 1991; Webb et al, 1991; Ferrini et al, 1994) have indicated that ICAM-1 expression on tumour cells is important for host immune, cell-mediated cytotoxicity. For example, cytokines such as IFN, TNF and IL-1 are able to increase ICAM-1 expression in cancer cell lines in vitro (e.g. HT-29 human colon tumour cells) and are reported to render the cells susceptible to macrophage-mediated killing (Webb et al, 1991) . Co-recognition of ICAM-1 and MHC class I is a vital for host cell-mediated tumour cytotoxicity (Vanky et al, 1990) .
According to previous reports, CDDP does not alter the expression of cell adhesion molecules on tumour cells (Yamaue et al, 1991; Mizutani et al, 1993) . In contrast, it is reported that a combination of CDDP and mitomycin C increases the expression of cell adhesion molecules on Daudi and KATO-III cells (Ishihata et al, 1996) . Our results demonstrate that combined treatment with CDDP and 5-FU can elevate the expression of ICAM-1 in a cancer cell line, suggesting that the clinically accepted synergistic antitumour effects of CDDP and 5-FU might be, at least partly, mediated by increasing antigen presentation to T-cells.
We also have shown that ICAM-2 and ICAM-3 expression on NA cells is not induced by CDDP and 5-FU. Both ICAM-2 and ICAM-3 bind to LFA-1 on T lymphocytes and activate them, but the activating signals transduced by ICAM-2 and ICAM-3 are weaker than ICAM-1. Thus, induction of ICAM-1 on cancer cells might be more important than induction of ICAM-2 or ICAM-3. In this regard, specific induction of ICAM-1 on cancer cells by CDDP and 5-FU is beneficial in generating optimal antigen presentation of cancer cells to T lymphocytes.
The synergistic effects of CDDP and 5-FU reported in this study are not specific to NA cells, since ICAM-1, not ICAM-2 and ICAM-3, was synergistically induced by CDDP and 5-FU on HSC-4 cells.
In this study, we also investigated the mechanisms by which CDDP and 5-FU induce the expression of ICAM-1 on cancer cells. Treatment of NA cells with genistein, a protein tyrosine kinase (PTK) inhibitor, resulted in abolishment of CDDP and 5-FU-induced ICAM-1 expression, whereas treatment with staurosporin, a protein kinase C inhibitor, did not inhibit ICAM-1 expression induced by CDDP and 5-FU. These results suggest that CDDP and 5-FU induced ICAM-1 expression via a tyrosine related pathway, though further experiments are necessary to isolate the exact mechanism.
We have shown that ICAM-1 regulation by CDDP and 5-FU occurs at the mRNA level. This observation suggests that CDDP and 5-FU target transcription factors interacting with ICAM-1 promoter elements. Previous reports have indicated that ICAM-1 expression is transcriptionally regulated, and the promoter contains binding sites for transcription factors such as NF-κB, AP-1 and C/EBP (Voraberger et al, 1991; Wawryk et al, 1991; Look et al, 1994) . Our results indicate that CDDP and 5-FU caused the accumulation of nuclear factor binding to proximal ICAM-1 NF-κB sites. However, suppression of NF-κB nuclear translocation by the inhibitor did not inhibit CDDP and 5-FUinduced ICAM-1 up-regulation. Furthermore, pretreatment with genistein did not reduce the formation of the specific NF-κB binding complex. These results suggest that NF-κB is not important for CDDP and 5-FU synergistic induction of ICAM-1 expression on cancer cells. Future experiments using transfection of the ICAM-1 promoter elements should determine if CDDP and 5-FU-induced ICAM-1 expression is regulated by NF-κB.
An alternative explanation for up-regulation of ICAM-1 may be via an autocrine mechanism involving cytokine. Epithelial cancer cells can produce some cytokines including IL-1α, IL-1β, TNF-α and IFN-γ, and they are reportedly able to induce the expression of ICAM-1 in various types of cells. Thus, NA cells stimulated by CDDP and 5-FU may secret these cytokines, which in turn stimulate NA cells in an autocrine manner to induce the expression of ICAM-1. However, treatment with CDDP and 5-FU did not induce production of either IL-1α, IL-1β or TNF-α in NA cells, as determined by ELISA and RT-PCR analysis. Thus, IL-1α, IL-1β and TNF-α are not involved in up-regulation of ICAM-1. In contrast, IFN-γ mRNA level was up-regulated by simultaneous treatment with CDDP and 5-FU. However, IFN-γ may not be responsible for induction of ICAM-1, since induction of ICAM-1 by CDDP and 5-FU was not inhibited by monoclonal antibody against IFN-γ.
The results of the present study further demonstrate that combined treatment with CDDP and 5-FU directly effects the expression and function of certain molecules engaged in cell-cell recognition and signalling on the surfaces of tumour cells. E-selectin and VCAM-1 are cell adhesion molecules mainly expressed on endothelial cells. They bind to their counterreceptors on cancer cells, and mediate the adhesion of cancer cells to endothelium (Rice and Bevilacqua, 1989; Lauri et al, 1991; Majuri et al, 1992) . Previous reports have indicated that the expression of sialyl Le x and sialyl Le a , counter-receptors for E-selectin, and very late antigen-4 (VLA-4), counter-receptor for VCAM-1, on cancer cells is closely related to their metastatic properties (Majuri et al, 1992; Iwai et al, 1993) . Although much attention has been paid to the expression of these cell adhesion molecules on cancer cells, less is known about the expression of Eselectin or VCAM-1 on cancer cells. Interestingly, the expression of E-selectin and VCAM-1 on NA cells was up-regulated by combined treatment with CDDP and 5-FU, though the significance of the induced expression, as well as the functions of these cell adhesion molecules on NA cells, is not clear.
Recently, the existence of soluble forms of ICAM-1 has been demonstrated in the serum of normal subjects, patients with autoimmune diseases, transplant rejection and malignancies. The increase in ICAM-1 serum levels in various neoplastic process has been associated with an unfavourable prognosis (Sanchez-Rovita et al, 1998) . The effect of CDDP and 5-FU on the level of soluble ICAM-1 in serum of patients with cancer remains to be examined. Increased expression of ICAM-1 on cancer cells by treatment with these anticancer agents suggests they can function as an immune modulator. Their effectiveness as cancer therapeutic agents may be increased if they increase the expression of ICAM-1 on cancer cells without increasing soluble ICAM-1 level.
